Latest news with #eProteinDiscovery™System
Business Wire
28-05-2025
- Business
- Business Wire
Nuclera and Cytiva Collaborate to Accelerate Characterization of Proteins for Drug Development
CAMBRIDGE, England & MARLBOROUGH, Mass.--(BUSINESS WIRE)--Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ System, has announced a collaboration with Cytiva, a global life sciences leader. This collaboration is focused on accelerating the production, purification and characterization of proteins required for drug research and development, enabled through the combination of Nuclera's eProtein Discovery System with Cytiva's Biacore™ surface plasmon resonance (SPR) technology. Proteins represent 95% of drug targets designed to combat disease. Rapid access to these proteins and understanding how they interact with drug candidates is essential for drug development. Typically, it takes months to obtain and characterize proteins, but Nuclera and Cytiva together have achieved production and characterization within five days. This achievement was showcased at industry conferences Discovery on Target and PEGS Europe, where Nuclera's eProtein Discovery System was used to produce Bruton's Tyrosine Kinase (BTK) and Vascular Endothelial Growth Factor (VEGF). These proteins were subsequently functionally characterized using Cytiva's Biacore SPR system. Dr. Yvonne Tan, Associate Director of Product Management, Nuclera, commented: 'Collaborating with life science leader Cytiva supports Nuclera in our mission of improving human health. Through this collaboration, we have demonstrated eProtein Discovery's ability to produce clinically significant proteins that can be used in characterization experiments. Combining eProtein Discovery's capability to streamline protein production workflows with Cytiva's Biacore protein characterization systems open a whole new avenue for accelerating drug development.' Anna Moberg, Senior Manager and Project Manager, Cytiva, added: 'The ability of Nuclera's eProtein Discovery to accelerate protein production and purification complements Cytiva's Biacore SPR technology by streamlining the upstream protein production process. We look forward to continuing our collaboration to further enhance the production of characterizable proteins for drug development.' For more information about Nuclera's eProtein Discovery System, please visit:
Business Wire
06-05-2025
- Business
- Business Wire
Nuclera Establishes Distribution Network Across APAC and the Middle East
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ System, today announced that it has established a distribution network across APAC and the Middle East. Marking a key milestone in the Company's global commercial strategy, the expansion establishes new regional distribution networks, providing localized technical support for customers in these key markets. In response to the rapidly growing demand for its innovative eProtein Discovery System, Nuclera has formed partnerships with seven channel partners: MineBio Life Sciences Ltd (China), Kiko Tech Co.,Ltd (Japan), CHAYON Laboratories, Inc. (South Korea), Sciencewerke Pte Ltd (Singapore), Cold Spring Biotech (Taiwan) and Yair Or Technologies Ltd (Israel). These new partnerships follow the recent expansion of the eProtein Discovery System, which now enables discovery of both membrane and soluble proteins 1. Proteins represent 95% of drug targets designed to combat disease 2 therefore developing reliable and efficient methods to identify how to express soluble and active proteins of interest is a crucial aspect of the drug discovery process. Researchers are realizing the value of systems, such as eProtein Discovery, that streamline protein production and enable rapid, scalable access to high-quality proteins, across cell-free and cell-based expression methods. 'Expanding into APAC and the Middle East, in response to growing global demand, demonstrates the potential of eProtein Discovery to revolutionize the way proteins are made,' Said Dr Michael Chen, CEO and co-founder, Nuclera. 'Testament to the growing demand are installations of eProtein Discovery at leading pharma and academic institutions and the first installation of our System within a CRO. We have partnered with established partners across key markets to enable specialized local support for our customers, enabling them to make proteins for drug discovery more efficiently and effectively.' Joseph Bertelsen, CCO, Nuclera, commented: 'We are excited to have extended our reach to the Middle East and Asia through partnering with key distributors Yair Or Technologies, Minebio, Chayon Laboratories, Kiko-Tech, ScienceWerke, and Cold Spring Biotech. Establishing these distribution channels supports our goal of global expansion and comes at a pivotal time for the Company as we are focused on ramping-up commercially following the successful close of our series C fundraising round.'
